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ABSTRACT 48 
Purpose 49 
Our aim was to evaluate the impact of intravitreal ranibizumab pre-treatment on the outcome 50 
of vitrectomy surgery for advanced proliferative diabetic retinopathy. The objective was to 51 
determine the feasibility of a subsequent definitive trial and estimate the effect size and 52 
variability of the outcome measure. 53 
Methods 54 
We performed a pilot randomised double-masked single-centre clinical trial in 30 participants 55 
with tractional retinal detachment associated with proliferative diabetic retinopathy. Seven 56 
days prior to vitrectomy surgery, participants were randomly allocated to receive either 57 
intravitreal ranibizumab (Lucentis®, Novartis Pharmaceuticals UK Ltd.) or subconjunctival 58 
saline (control). The primary outcome was best-corrected visual acuity 12 weeks following 59 
surgery. 60 
Results 61 
At 12 weeks the mean (SD) visual acuity was 46.7 (25) ETDRS letters in the control group 62 
and 52.6 (21) letters in the ranibizumab group. Mean visual acuity improved by 14 (31) 63 
letters in the control group and by 24 (27) letters in the ranibizumab group. We found no 64 
difference in the progression of tractional retinal detachment prior to surgery, the duration of 65 
surgery or its technical difficulty. Vitreous cavity haemorrhage persisted at 12 weeks in 2 of 66 
the control group but none of the ranibizumab group. 67 
Conclusions 68 
Ranibizumab pre-treatment may improve the outcome of vitrectomy surgery for advanced 69 
proliferative diabetic retinopathy by reducing the extent of postoperative vitreous cavity 70 
haemorrhage. However, the effect size appears to be modest; we calculate that a definitive 71 
study to establish a minimally important difference of 5.9 letters at a significance level of 72 
P<0.05 would require 348 subjects in each arm. 73 
  74 
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INTRODUCTION 75 
Advanced proliferative retinopathy is characterized by fibrovascular proliferation, vitreous 76 
haemorrhage and tractional retinal detachment (Figure 1A and B). This condition is 77 
conventionally managed by vitreoretinal surgery, the outcome of which can be limited by 78 
recurrent postoperative vitreous cavity haemorrhage.1,2 The intraocular administration of 79 
therapeutic anti-vascular endothelial growth factor (VEGF) antibodies is variably used as an 80 
adjunct to vitrectomy with the aim of improving the outcome by facilitating safe delamination 81 
of fibrovascular membranes and reducing the incidence of post-operative vitreous cavity 82 
haemorrhage.3-8 However the value of adjunctive administration of antiVEGF antibodies has 83 
yet to be established with confidence. 84 
Intravitreal ranibizumab pre-treatment, 7 days prior to vitrectomy surgery for diabetic 85 
tractional retinal detachment, can reduce intraoperative haemorrhage.9 The aim of the 86 
present study was to evaluate its impact on postoperative outcomes. The objective was to 87 
measure the effect on visual acuity and ascertain the number of participants that would be 88 
needed to determine such an effect with confidence. 89 
 90 
MATERIALS AND METHODS 91 
We performed a randomised double-masked parallel group pilot study at Moorfields Eye 92 
Hospital (NCT01306981). The study conformed to the Declaration of Helsinki and was 93 
approved prospectively by the Central London Research Ethics Committee 1 of the UK 94 
National Research Ethics Service. All participants gave their informed consent to participate 95 
in the research prior to enrolment.  96 
We included 30 eyes of 30 adult participants having vitrectomy and delamination surgery for 97 
advanced proliferative diabetic retinopathy with fibrovascular complexes and/or tractional 98 
retinal detachment. Eyes with persistent vitreous haemorrhage could be included because of 99 
the use of ultrasonography to evaluate attachment of the retina. We excluded eyes having 100 
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planned combined cataract and vitrectomy, those with only a single focal point of 101 
vitreoretinal attachment apparent on clinical examination or ultrasonography, and those with 102 
cataract or uncontrolled glaucoma. We excluded individuals with visual acuity in the 103 
contralateral eye of 3/60 or poorer, hypersensitivity to the active substance or excipients, 104 
and cerebrovascular, cardiovascular or peripheral vascular disease. 105 
 106 
Seven days (±1 day) prior to vitrectomy surgery, participants were randomly allocated 1:1 to 107 
receive either intravitreal ranibizumab (Lucentis®, 0.5 mg in 0.05 ml solution for injection, 108 
Novartis Pharmaceuticals UK Ltd., Frimley, United Kingdom), or subconjunctival saline 109 
control (sodium chloride, 0.05ml of 0.9% solution for injection) using a 1ml syringe and 30-110 
gauge needle. Randomisation was performed using random permuted blocks of varying 111 
sizes. The allocation sequence was held by the trial statistician and concealed from the 112 
investigator enrolling and assessing participants. An unmasked investigator administered the 113 
study agents. Participants in both groups were prepared identically using topical anaesthetic 114 
and povidone iodine; topical levofloxacin was administered immediately prior to the injection 115 
and 4 times daily for 4 days. The participants, operating surgeons and assessing 116 
investigators were masked to treatment allocation. Participants were assessed at baseline, 117 
immediately prior to surgery, and at 6 weeks and 12 weeks following surgery. 118 
 119 
Experienced vitreoretinal surgeons performed 20-gauge pars plana vitrectomy and en-bloc 120 
delamination of fibrovascular membranes, panretinal endo-photocoagulation, with retinopexy 121 
and endotamponnade if indicated. We recorded the duration of surgery, the number of back-122 
flush cannula and endodiathermy applications required to control haemorrhage, retinal 123 
breaks, intraoperative bleeding score (0-none; 1-mild, stopped by bottle elevation; 2-124 
moderate, forming clots or persistent; 3-severe, covering half of posterior pole) and the 125 
anticipated surgical complexity score (Castellarin et al.).10 126 
 127 
To investigate the impact of ranibizumab on the extent of tractional retinal detachment prior 128 
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to surgery we examined the study eye prior to administration of the study agent and one 129 
week later on the day of surgery by slit-lamp biomicroscopy and ultrasonography (Acuson 130 
Sequoia 512 scanner, 14 MHz linear probe; Siemens Medical Solutions USA; Mountain 131 
View, CA, USA). To investigate the impact on retinal neovascularisation and ischaemia we 132 
performed fluorescein angiography (unless precluded by vitreous haemorrhage); masked 133 
assessors at Moorfields Reading Centre measured the greatest linear dimension and area of 134 
the foveal avascular zone, and the grade of perifoveal capillary non-perfusion. 135 
 136 
The primary outcome measure was Early Treatment Diabetic Retinopathy Study (ETDRS) 137 
best-corrected visual acuity 12 weeks following surgery. Secondary outcome measures 138 
included the extent of tractional retinal detachment and macular perfusion at the time of 139 
surgery; the technical ease of vitrectomy surgery including duration, instrument usage and 140 
intra-operative haemorrhage; and the presence of post-operative vitreous cavity 141 
haemorrhage. This was graded using a previously described scale from 0 – 3 (0 – no 142 
haemorrhage, clear view; 1 – minor haemorrhage with fundus details visible; 2 – moderate 143 
haemorrhage with only disc and major vessels visible; 3 – severe haemorrhage with fundus 144 
details not visible). 11 145 
 146 
For this pilot trial we performed no formal sample size calculation but estimated that 30 147 
subjects would be sufficient to explore the feasibility of a subsequent definitive trial and to 148 
enable calculation of its sample size. The Trial Steering Group approved a statistical 149 
analysis plan prior to analysis of data. We compared baseline characteristics of the 150 
participants allocated to the 2 treatment arms. Normality was assessed by inspection of 151 
histograms. We calculated summary statistics using STATA statistical software (version 12, 152 
StataCorp LP, College Station, TX, USA).  153 
 154 
  155 
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RESULTS 156 
We included 30 eyes of 30 participants and randomly allocated 15 eyes to each arm of the 157 
study, and none were lost to follow-up. All eyes had been managed for proliferative 158 
retinopathy by panretinal photocoagulation prior to enrolment. The participants in the 2 arms 159 
were similar (Table 1) though the overall complexity score derived from ultrasound 160 
assessment of tractional detachment was slightly higher in the ranibizumab group (Table 2).  161 
 162 
At 12 weeks following surgery the mean (standard deviation) visual acuity was 46.7 (25) 163 
ETDRS letters in the control group and 52.6 (21) letters in the ranibizumab group (Figure 2). 164 
The mean visual acuity improved by 14 (31) letters in the control group and by 24 (27) letters 165 
in the ranibizumab group. 166 
 167 
One participant in each group developed new tractional retinal detachment following the 168 
study injection; in neither instance did this involve the macula (Table 2). The mean height of 169 
TRD increased slightly in control eyes following the study injection. No other change in TRD 170 
dimension exceeded the limit of resolution (±1.6 mm) and the overall ultrasound-derived 171 
complexity score was unchanged in both groups. 172 
 173 
The median duration of surgery was greater in the ranibizumab group (63 minutes) than the 174 
control group (51 minutes) (Table 3; P=0.53); intraoperative haemorrhage scores were 175 
similar as were the number of endodiathermy and back-flush cannula applications. The 176 
median surgeon-defined complexity score based on retinal features present at the start of 177 
surgery was slightly higher for the ranibizumab group but the median overall subjective 178 
surgical difficulty score was lower and there were fewer iatrogenic retinal breaks. 179 
 180 
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Any residual vitreous cavity haemorrhage following vitrectomy surgery resolved 181 
progressively in both groups. At six weeks after surgery two of fifteen subjects in the control 182 
group, and one of thirteen subjects in the ranibizumab group who had not received silicone 183 
oil had visible vitreous cavity haemorrhage. While this was moderate in the ranibizumab 184 
group, in the control group both had a severe grade of haemorrhage. Moderate or severe 185 
residual haemorrhage persisted in 2 eyes of the control group at 12 weeks following surgery, 186 
but had fully resolved in the subject in the ranibizumab group. 187 
 188 
At baseline, fluorescein angiograms were gradable in only a minority of participants (3 of the 189 
control group and 5 of the ranibizumab group) owing to media opacity and/or distortion of 190 
foveal anatomy in the majority. All gradable angiograms demonstrated moderate to severe 191 
perifoveal capillary non-perfusion. At 12 weeks, the mean (SD) foveal avascular zone 192 
greatest linear dimension was 637 (236) µm in the control group (n=9) and 765 (576) µm in 193 
the ranibizumab group (n=10); the foveal avascular zone area was 0.315 (0.147) mm2 in the 194 
control group and 0.403 (0.562) mm2 in the ranibizumab group. The median total score for 195 
perifoveal capillary non-perfusion was 14 in both groups, indicating scores of 3-4 (moderate 196 
to severe) in each of the four quadrants.  197 
Ocular and non-ocular adverse events were in keeping with previously published trials of 198 
anti-VEGF agents. The most common adverse event was upper respiratory tract infection 199 
which occurred more commonly in the control group. There were no arterial thrombo-embolic 200 
events or cases of endophthalmitis. There was one serious adverse event in each group. 201 
One participant in the control group was admitted to hospital for management of 202 
hypoglycaemia 10 weeks after surgery, and one participant in the ranibizumab group was 203 
admitted for management of raised intraocular pressure following vitrectomy surgery, an 204 
event judged unlikely to be related to study drug administration. Vitreous cavity haemorrhage 205 
was more frequent in the control group than in the ranibizumab group.   206 
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DISCUSSION 207 
The results of this trial confirm significant improvement in mean visual acuity 12 weeks 208 
following vitreoretinal surgery for advanced proliferative retinopathy, with or without 209 
ranibizumab pre-treatment, consistent with previous reports. 1 Our findings also suggest a 210 
modest additional benefit of intravitreal injection of ranibizumab one week prior to surgery, 211 
with higher mean visual acuity and greater mean improvement in visual acuity at 12 weeks. 212 
The difference in acuity in this pilot study is not statistically significant.  On the basis of these 213 
data, we calculate that 348 subjects in each group (696 in total) would be required to 214 
determine a clinically relevant treatment difference of 5.9 letters with 90% power and 5% 215 
significance, allowing for 5% loss to follow-up. 216 
Our findings of reduced postoperative vitreous cavity haemorrhage associated with 217 
ranibizumab pre-treatment in vitrectomy surgery are consistent with a previous report that 218 
this also reduces intraoperative haemorrhage during surgery. 9 Earlier studies have shown 219 
conflicting results regarding the utility of bevacizumab in preventing recurrent haemorrhage, 220 
for example Romano et al. found that although pre-operative injection could reduce the 221 
number of recurrent haemorrhages, 12 giving the drug as an intra-operative adjunct did not 222 
prevent post-operative vitreous cavity haemorrhage. 11 Data from the 2015 update to the 223 
Cochrane review of bevacizumab for the prevention of post-operative vitreous cavity 224 
haemorrhage suggest that treatment results in 130 fewer people per 1000 experiencing early 225 
post-operative haemorrhage, although there is considerable heterogeneity of methodology in 226 
the trials included in this systematic review. 8  227 
We found that ranibizumab pre-treatment was associated with a lower intraoperative 228 
bleeding score, greater reduction in retinal neovascularisation and lower prevalence of 229 
persistent vitreous cavity haemorrhage. However,  in contrast to previous studies and a 230 
meta-analysis of these studies that have reported shorter surgical duration or fewer 231 
instrument exchanges following anti-VEGF prior to surgery for proliferative diabetic 232 
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retinopathy,4,7 we found that the median surgical complexity score was no lower, the mean 233 
duration of vitrectomy was no shorter, and the use of the backflush cannula and 234 
endodiathermy were similar. 235 
Previous studies have highlighted concerns about the development or progression of 236 
tractional retinal detachment associated with progressive fibrosis following intravitreal 237 
administration of anti-VEGF agents, especially in the absence of prior panretinal 238 
photocoagulation.13,14 Despite the presence of dense media opacity in many, we were able 239 
to determine the impact of ranibizumab pre-treatment on the extent of tractional retinal 240 
detachment prior to surgery in all participants by the use of ultrasonography. In our study, in 241 
which all subjects had been managed previously by panretinal photocoagulation, we 242 
identified no effect of ranibizumab injection on extension of retinal detachment after 7 days. 243 
We chose this interval between injection and surgery to maximise the possibility of benefit 244 
while minimising the risk of harm, and this finding from ultrasound evaluation suggests that 245 
administering ranibizumab in the setting of previously treated proliferative retinopathy may 246 
be safe in this regard.  247 
We identified significant macular ischemia in the participants in both groups but found no 248 
evidence of an impact of intervention in either. Although we conclude that its safety profile 249 
appears to be favourable, the number of subjects in whom angiography was feasible is 250 
insufficient to draw firm conclusions about the impact of ranibizumab injection on the extent 251 
of macular ischemia in this context.  252 
The strengths of our study are that it was randomised and double-masked with a sham 253 
control arm. Since the study included multiple surgeons, all of whom were experienced in 254 
vitrectomy surgery for advanced diabetic retinopathy, the findings are broadly generalisable. 255 
The ability to draw firm conclusions is limited by the small number of subjects included and 256 
the inherent heterogeneity of the condition, in particular the variability of management of 257 
proliferative retinopathy prior to enrolment in the study and difficulty in controlling for variable 258 
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amounts of prior panretinal photocoagulation. However, the results provide a valuable 259 
indication of the substantial size of the trial that would be needed to confirm with confidence 260 
the impact of ranibizumab pre-treatment in vitrectomy surgery for advanced diabetic 261 
retinopathy. 262 
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 FIGURE LEGENDS 274 
Figure 1A and B – Colour fundus photograph (A) and ultrasound image (B) to show 275 
advanced proliferative diabetic retinopathy. The fundus image shows evidence of 276 
fibrovascular proliferation, pre-retinal haemorrhage and tractional retinal detachment 277 
involving the macula, while the ultrasound shows partial posterior vitreous detachment with 278 
vitreous attachment to tractional retinal detachment. Calliper placement shows measurement 279 
of height and longitudinal base dimension of tractional detachment. 280 
 281 
Figure 2 – Box plots to show visual acuity (VA) by treatment group, shown as mean ± 282 
standard deviation Early Treatment Diabetic Retinopathy Study letter score  283 
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